Alpha Teknova, Inc. (TKNO) News
Filter TKNO News Items
TKNO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest TKNO News From Around the Web
Below are the latest news stories about ALPHA TEKNOVA INC that investors may wish to consider to help them evaluate TKNO as an investment opportunity.
Alpha Teknova Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAlpha Teknova ( NASDAQ:TKNO ) Third Quarter 2024 Results Key Financial Results Revenue: US$9.58m (up 17% from 3Q 2023... |
Alpha Teknova: Q3 Earnings SnapshotTKNO) on Thursday reported a loss of $7.6 million in its third quarter. On a per-share basis, the Hollister, California-based company said it had a loss of 15 cents. The maker of reagents used by the biopharmaceutical industry posted revenue of $9.6 million in the period. |
Teknova Reports Third Quarter 2024 Financial ResultsThird quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today a |
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. Teknova will host a webcast and conference call on Thursday, November 7 |
Several Factors Lifted Alpha Teknova (TKNO) in Q3Conestoga Capital Advisors, an asset management company, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. At its September meeting, the Federal Reserve lowered the Federal Funds rate by 50 basis points due to weaker employment growth and moderate inflation. Equity markets welcomed the news, raising optimism for a soft landing in […] |
What Makes Alpha Teknova (TKNO) a Strong Momentum Stock: Buy Now?Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out. |
Alpha Teknova Market Cap Surges to $257M Following Insider Buying SpreeInsider Confidence Propels Alpha Teknova Stock Up 11%" |
Here’s Why Alpha Teknova (TKNO) Underperformed in Q2Conestoga Capital Advisors, an asset management company, released its “Micro-Cap Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. The second quarter of 2024 may be regarded as a time of moderation. Economic indicators largely reflected slowing growth and easing inflation. The moderation theme also drives equity markets. Large-cap stocks, as measured […] |
Alpha Teknova: Q2 Earnings SnapshotTKNO) on Tuesday reported a loss of $5.4 million in its second quarter. On a per-share basis, the Hollister, California-based company said it had a loss of 13 cents. The maker of reagents used by the biopharmaceutical industry posted revenue of $9.6 million in the period. |
Teknova Reports Second Quarter 2024 Financial ResultsSecond quarter 2024 total revenue was $9.6 million, up 3% sequentiallyRaised $15.4 million of equity capital in July 2024Launched two new offerings: Express-TekSM Production and RUO+ manufacturing gradeCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines |